Pott H, Weckler B, Gaffron S, Martin R, Maier D, Alter P
Respirology. 2024; 30(2):134-146.
PMID: 39448064
PMC: 11788467.
DOI: 10.1111/resp.14843.
Meldrum O, Donaldson G, Narayana J, Ivan F, Jaggi T, Mac Aogain M
Am J Respir Crit Care Med. 2024; 210(3):298-310.
PMID: 38315959
PMC: 11348959.
DOI: 10.1164/rccm.202306-1060OC.
Jespersen T, Bach Kampmann F, Dantoft T, Jorgensen N, Karhus L, Madsen F
ERJ Open Res. 2023; 9(5).
PMID: 37588689
PMC: 10423920.
DOI: 10.1183/23120541.00208-2023.
Shah H, Shah M, Mahathevan K
Cureus. 2023; 14(12):e32454.
PMID: 36644074
PMC: 9834669.
DOI: 10.7759/cureus.32454.
Martinez F, Agusti A, Celli B, Han M, Allinson J, Bhatt S
Am J Respir Crit Care Med. 2021; 205(3):275-287.
PMID: 34672872
PMC: 8886994.
DOI: 10.1164/rccm.202107-1663SO.
The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study.
Mostafa T, El-Azab G, Atia G, Lotfy N
Curr Ther Res Clin Exp. 2021; 94:100625.
PMID: 34306265
PMC: 8296082.
DOI: 10.1016/j.curtheres.2021.100625.
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
Singh D, Criner G, Dransfield M, Halpin D, Han M, Lange P
Respir Res. 2021; 22(1):130.
PMID: 33910578
PMC: 8080358.
DOI: 10.1186/s12931-021-01706-y.
Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.
Celli B, Locantore N, Yates J, Bakke P, Calverley P, Crim C
Eur Respir J. 2020; 57(3).
PMID: 33303557
PMC: 7991608.
DOI: 10.1183/13993003.01339-2020.
Peripheral blood CD4+ T cell populations by CD25 and Foxp3 expression as a potential biomarker: reflecting inflammatory activity in chronic obstructive pulmonary disease.
Meng Z, Wu J, Zhou M, Sun S, Miao S, Han H
Int J Chron Obstruct Pulmon Dis. 2019; 14:1669-1680.
PMID: 31440043
PMC: 6679698.
DOI: 10.2147/COPD.S208977.
Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort.
Ronnow S, Sand J, Langholm L, Manon-Jensen T, Karsdal M, Tal-Singer R
Respir Res. 2019; 20(1):63.
PMID: 30935391
PMC: 6444812.
DOI: 10.1186/s12931-019-1026-x.
Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort.
Ronnow S, Langholm L, Sand J, Thorlacius-Ussing J, Leeming D, Manon-Jensen T
Sci Rep. 2019; 9(1):4064.
PMID: 30858579
PMC: 6412140.
DOI: 10.1038/s41598-019-40785-2.
Annual change in FEV in elderly 10-year survivors with established chronic obstructive pulmonary disease.
Suzuki M, Makita H, Konno S, Shimizu K, Nasuhara Y, Nagai K
Sci Rep. 2019; 9(1):2073.
PMID: 30765818
PMC: 6375910.
DOI: 10.1038/s41598-019-38659-8.
Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD.
AboEl-Magd G, Mabrouk M
J Bras Pneumol. 2018; 44(1):36-41.
PMID: 29538541
PMC: 6104538.
DOI: 10.1590/S1806-37562017000000151.
Biomarkers of collagen turnover are related to annual change in FEV in patients with chronic obstructive pulmonary disease within the ECLIPSE study.
Leeming D, Byrjalsen I, Sand J, Bihlet A, Lange P, Thal-Singer R
BMC Pulm Med. 2017; 17(1):164.
PMID: 29202744
PMC: 5716018.
DOI: 10.1186/s12890-017-0505-4.
Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity.
Lee H, Jhun B, Cho J, Yoo K, Lee J, Kim D
Int J Chron Obstruct Pulmon Dis. 2017; 12:3301-3310.
PMID: 29180860
PMC: 5691931.
DOI: 10.2147/COPD.S145910.
The EASI model: A first integrative computational approximation to the natural history of COPD.
Agusti A, Compte A, Faner R, Garcia-Aymerich J, Noell G, Cosio B
PLoS One. 2017; 12(10):e0185502.
PMID: 29016620
PMC: 5634586.
DOI: 10.1371/journal.pone.0185502.
Identification of thyroxine-binding globulin as a candidate plasma marker of chronic obstructive pulmonary disease.
Diao W, Shen N, Du Y, Sun X, Liu B, Xu M
Int J Chron Obstruct Pulmon Dis. 2017; 12:1549-1564.
PMID: 28579773
PMC: 5448702.
DOI: 10.2147/COPD.S137806.
Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers.
Obeidat M, Nie Y, Fishbane N, Li X, Bosse Y, Joubert P
Am J Respir Cell Mol Biol. 2017; 57(4):411-418.
PMID: 28459279
PMC: 5650084.
DOI: 10.1165/rcmb.2016-0284OC.
Identification of subtypes in subjects with mild-to-moderate airflow limitation and its clinical and socioeconomic implications.
Lee J, Rhee C, Kim K, Kim J, Kim S, Yoo K
Int J Chron Obstruct Pulmon Dis. 2017; 12:1135-1144.
PMID: 28442900
PMC: 5396836.
DOI: 10.2147/COPD.S130140.
Fetuin-B (FETUB): a Plasma Biomarker Candidate Related to the Severity of Lung Function in COPD.
Diao W, Shen N, Du Y, Liu B, Sun X, Xu M
Sci Rep. 2016; 6:30045.
PMID: 27443820
PMC: 4957096.
DOI: 10.1038/srep30045.
